Mood-stabilizing drugs: mechanisms of action
- PMID: 22217451
- DOI: 10.1016/j.tins.2011.11.009
Mood-stabilizing drugs: mechanisms of action
Abstract
Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.
Similar articles
-
Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?Psychiatr Clin North Am. 2005 Jun;28(2):399-414. doi: 10.1016/j.psc.2005.02.002. Psychiatr Clin North Am. 2005. PMID: 15826739 Review.
-
New understanding of mechanisms of action of bipolar medications.J Clin Psychiatry. 2008;69 Suppl 5:22-7. J Clin Psychiatry. 2008. PMID: 19265637 Review.
-
Drugs for depression and bipolar disorder.Treat Guidel Med Lett. 2010 May;8(93):35-42. Treat Guidel Med Lett. 2010. PMID: 20414177 Review. No abstract available.
-
Pediatric bipolar disorder: evidence-based psychopharmacological treatments.J Child Adolesc Psychiatr Nurs. 2007 Feb;20(1):40-58. doi: 10.1111/j.1744-6171.2007.00083.x. J Child Adolesc Psychiatr Nurs. 2007. PMID: 17284237 Review.
-
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.Biol Psychiatry. 2006 Jun 1;59(11):1006-20. doi: 10.1016/j.biopsych.2005.10.021. Epub 2006 Feb 17. Biol Psychiatry. 2006. PMID: 16487491 Review.
Cited by
-
A safe lithium mimetic for bipolar disorder.Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320. Nat Commun. 2013. PMID: 23299882 Free PMC article.
-
Transition of Neural Activity From the Chaotic Bipolar-Disorder State to the Periodic Healthy State Using External Feedback Signals.Front Comput Neurosci. 2020 Aug 28;14:76. doi: 10.3389/fncom.2020.00076. eCollection 2020. Front Comput Neurosci. 2020. PMID: 32982709 Free PMC article.
-
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.Psychopharmacology (Berl). 2020 Jul;237(7):2139-2149. doi: 10.1007/s00213-020-05525-9. Epub 2020 May 9. Psychopharmacology (Berl). 2020. PMID: 32388618 Free PMC article.
-
Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder.Bipolar Disord. 2015 May;17(3):248-56. doi: 10.1111/bdi.12260. Epub 2014 Sep 25. Bipolar Disord. 2015. PMID: 25257942 Free PMC article.
-
Mood stabilizing drugs regulate transcription of immune, neuronal and metabolic pathway genes in Drosophila.Psychopharmacology (Berl). 2016 May;233(9):1751-62. doi: 10.1007/s00213-016-4223-z. Epub 2016 Feb 6. Psychopharmacology (Berl). 2016. PMID: 26852229
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
